Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Daiichi Sankyo Wins 203 Billion Yen Lawsuit over Fortis Bid
Daiichi Sankyo said on September 10 that the Tokyo District Court has dismissed all claims in a 203.3 billion yen damages lawsuit brought by a unit of Malaysian hospital group IHH Healthcare over its stalled bid for India’s Fortis Healthcare.…
To read the full story
Related Article
- IHH Unit Appeals Dismissal of 203 Billion Yen Daiichi Sankyo Suit
September 28, 2026
- Daiichi Sankyo Sued by Malaysia Hospital Group over TOB Interference
November 28, 2023
- Ex-Ranbaxy Shareholders Ordered to Pay 56 Billion Yen to Daiichi Sankyo
May 9, 2016
- Daiichi Sankyo: Ranbaxy Former Shareholders Hid Critical Information
May 24, 2013
BUSINESS
- LinDo Sets Sights on More Pediatric Deals as It Builds Drug-Loss Portfolio
October 6, 2026
- Shionogi to Buy IntraBio for US$2 Billion, Gains Rare Disease Drug
October 6, 2026
- Fujifilm AI Finds Potent New Inhibitors from Known Compound
October 6, 2026
- Boehringer’s Survodutide Makes Mark in Japan PIII Obesity Trial
October 6, 2026
- Kyowa Finds Nitrosamines in 2 Antidepressants; No Recall Planned
October 6, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…